|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of ıncidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bostwick DG, Burke HB, Djakiew D, Euling
S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters
DJ and Timms B: Human prostate cancer risk factors. Cancer. 101 (10
Suppl):S2371–S2490. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dobbs RW, Malhotra NR, Greenwald DT, Wang
AY, Prins GS and Abern MR: Estrogens and prostate cancer. Prostate
Cancer Prostatic Dis. 22:185–194. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Setlur SR, Mertz KD, Hoshida Y, Demichelis
F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA,
et al: Estrogen-dependent signaling in a molecularly distinct
subclass of aggressive prostate cancer. J Natl Cancer Inst.
100:815–825. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McPherson SJ, Hussain S, Balanathan P,
Hedwards SL, Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang
Y, Taylor RA and Risbridger GP: Estrogen receptor-beta activated
apoptosis in benign hyperplasia and cancer of the prostate is
androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA.
107:3123–3128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mak P, Leav I, Pursell B, Bae D, Yang X,
Taglienti CA, Gouvin LM, Sharma VM and Mercurio AM: ERβ ımpedes
prostate cancer EMT by destabilizing HIF-1α and inhibiting
VEGF-mediated snail nuclear localization: Implications for gleason
grading. Cancer Cell. 17:319–332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Risbridger G, Wang H, Young P, Kurita T,
Wang YZ, Lubahn D, Gustafsson JA and Cunha G: Evidence that
epithelial and mesenchymal estrogen receptor-α mediates effects of
estrogen on prostatic epithelium. Dev Biol. 229:432–442. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prins GS, Birch L, Couse JF, Choi I,
Katzenellenbogen B and Korach KS: Estrogen imprinting of the
developing prostate gland is mediated through stromal estrogen
receptor alpha: Studies with alphaERKO and betaERKO mice. Cancer
Res. 61:6089–6097. 2001.PubMed/NCBI
|
|
9
|
Bonkhoff H, Fixemer T, Hunsicker I and
Remberger K: Estrogen receptor expression in prostate cancer and
premalignant prostatic lesions. Am J Pathol. 155:641–647. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao
Y, McNeal JE and Ho SM: Dynamic regulation of estrogen
receptor-beta expression by DNA methylation during prostate cancer
development and metastasis. Am J Pathol. 164:2003–2012. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang X, Leung YK and Ho SM: AP-2
regulates the transcription of estrogen receptor (ER)-beta by
acting through a methylation hotspot of the 0N promoter in prostate
cancer cells. Oncogene. 26:7346–7354. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng J, Lee EJ, Madison LD and Lazennec
G: Expression of estrogen receptor beta in prostate carcinoma cells
inhibits invasion and proliferation and triggers apoptosis. FEBS
Lett. 566:169–172. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weihua Z, Warner M and Gustafsson JA:
Estrogen receptor beta in the prostate. Mol Cell Endocrinol.
193:1–5. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McPherson SJ, Ellem SJ, Simpson ER,
Patchev V, Fritzemeier KH and Risbridger GP: Essential role for
estrogen receptor beta in stromal-epithelial regulation of
prostatic hyperplasia. Endocrinology. 148:566–574. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Megas G, Chrisofos M, Anastasiou I,
Tsitlidou A, Choreftaki T and Deliveliotis C: Estrogen receptor (α
and β) but not androgen receptor expression is correlated with
recurrence, progression and survival in post prostatectomy T3N0M0
locally advanced prostate cancer in an urban Greek population.
Asian J Androl. 17:98–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grindstad T, Skjefstad K, Andersen S, Ness
N, Nordby Y, Al-Saad S, Fismen S, Donnem T, Khanehkenari MR, Busund
LT, et al: Estrogen receptors α and β and aromatase as independent
predictors for prostate cancer outcome. Sci Rep. 6:331142016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Horvath LG, Henshall SM, Lee CS, Head DR,
Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G,
et al: Frequent loss of estrogen receptor-β expression in prostate
cancer. Cancer Res. 61:5331–5335. 2001.PubMed/NCBI
|
|
18
|
Nelson JB and Lepor H: Prostate cancer:
Radical prostatectomy. Urol Clin North Am. 30:703–723. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bonkhoff H: Estrogen receptor signaling in
prostate cancer: Implications for carcinogenesis and tumor
progression. Prostate. 78:2–10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qu LG, Wardan H, Davis ID, Pezaro C and
Sluka P: Effects of estrogen receptor signaling on prostate cancer
carcinogenesis. Transl Res. 222:56–66. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He Y, Xu W, Xiao YT, Huang H, Gu D and Ren
S: Targeting signaling pathways in prostate cancer: Mechanisms and
clinical trials. Signal Transduct Target Ther. 7:1982022.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mottet N, Vice-Chair PC, Bergh RCN, Van
Den, Mottet N, et al: Guidelines on Prostate Cancer. Update.
53:31–45. 2021.
|
|
23
|
Briganti A, Karnes JR, Da Pozzo LF,
Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C,
Fazio F, et al: Two positive nodes represent a significant Cut-off
value for cancer specific survival in patients with node positive
prostate cancer. A new proposal based on a Two-ınstitution
experience on 703 consecutive N+ patients treated with radical
prostatectomy, extended pelvic lymph node dissection and adjuvant
therapy. Eur Urol. 55:261–270. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thompson IM, Tangen CM, Paradelo J, Lucia
MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, et
al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer
significantly reduces risk of metastases and ımproves survival:
Long-term followup of a randomized clinical trial. J Urol.
181:956–962. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bolla M, Van Poppel H, Tombal B, Vekemans
K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven
R, Colombel M, et al: Postoperative radiotherapy after radical
prostatectomy for high-risk prostate cancer: Long-term results of a
randomised controlled trial (EORTC trial 22911). Lancet.
380:2018–2027. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wiegel T, Bartkowiak D, Bottke D, Bronner
C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A,
et al: Adjuvant radiotherapy versus wait-and-see after radical
prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95
trial. Eur Urol. 66:243–250. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hackman G, Taari K, Tammela TL, Matikainen
M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A,
et al: Randomised trial of adjuvant radiotherapy following radical
prostatectomy versus radical prostatectomy alone in prostate cancer
patients with positive margins or extracapsular extension. Eur
Urol. 76:586–595. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shapiro E, Huang H, Masch RJ, McFadden DE,
Wilson EL and Wu XR: Immunolocalization of estrogen receptor α and
β in human fetal prostate. J Urol. 174:2051–2053. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Prins GS and Korach KS: The role of
estrogens and estrogen receptors in normal prostate growth and
disease. Steroids. 73:233–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weihua Z, Makela S, Andersson LC, Salmi S,
Saji S, Marketon JW, Jensen EV, Nilsson S, Warner M and Gustafsson
JA: A role for estrogen receptor? in the regulation of the ventral
prostate. Proce National Acad Sci. 98:6330–6335. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Terlizzi M, Limkin EJ, Moukasse Y and
Blanchard P: Adjuvant or salvage radiation therapy for prostate
cancer after prostatectomy: Current status, controversies and
perspectives. Cancers (Basel). 14:16882022. View Article : Google Scholar : PubMed/NCBI
|
